The multidisciplinary team of GI providers, gut-brain specialists, and registered dietitians at Oshi Health can offer a tailored treatment plan to help you implement the lifestyle and behavioral adjustments needed to reduce GI side effects associated with GLP-1 drugs
With activist investors bemoaning returns on R&D and M&A investment and the loss of about $17bn in revenues looming from exclusivity expiries in 20252030, the company has been culling its pipeline and looking externally for assets
This marks the world's first approved "PD-1+ADC" combination therapy
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
Recent antibiotic use combined with GLP-1 therapy may increase the risk of digestive disturbances and should be mentioned to your healthcare provider
20492057, Jul
